Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters










Publication year range
1.
Front Immunol ; 14: 1290740, 2023.
Article in English | MEDLINE | ID: mdl-37954580

ABSTRACT

Introduction: Obesity can complicate IgE-mediated allergic diseases. In the present study, we aimed to investigate the ability of obesity-related concentrations of leptin to modulate the in vitro effector and regulatory Fel d1-specific CD4+ T-cell subsets in patients allergic to cat, considered the third most common cause of respiratory allergy in humans. Methods: For this study, plasma and peripheral blood mononuclear cells (PBMC) from 30 cat-allergic patients with mild, moderate and severe respiratory symptoms were obtained. The PBMC cultures were stimulated with Fel d1 antigen (10 µg/mL) in the presence or absence of obesity-related leptin dose (50 ηg/mL). After 6 days, the levels of cytokines and IgE in the supernatants were evaluated by multiplex and ELISA, respectively. The frequency of different non-follicular (CXCR5-) and follicular (CXCR5+) Fel d1-specific CD4+ T cell subsets was determined by flow cytometry. The plasma levels of leptin and IgE anti-cat titers were evaluated by ELISA and ImmunoCAP, respectively. Results and conclusions: Fel d1 induced both IgE production and release of cytokines related to Th2, Th9 and Th17 cell phenotypes. Feld1 was more efficient in increasing the frequency of TFHIL-21- cells positive for IL-4, IL-5 and IL-13 than TFHIL-21+ cell subsets. Leptin favored the expansion Th2-like and Th9-like cells and TFHIL-21- cells positive for IL-4, IL-5 and IL-13, but reduced the proportion of conventional (Treg/Tr-1) and follicular (TFR) regulatory CD4+ T-cell subsets expressing or not CD39 marker. Finally, many of the imbalances between Fel d1-specific CD4+ T-cells were also correlated with plasma leptin and anti-Fel d1 IgE titers. In summary, hyperleptinemia should negatively impact on the severity of cat allergies by favoring the expansion of pathogenic Fel d1-specific CD4+ T-cell phenotypes and damaging the functional status of regulatory CD4+ T-cell subsets.


Subject(s)
Hypersensitivity , Leukocytes, Mononuclear , Humans , CD4-Positive T-Lymphocytes , Cytokines , Immunoglobulin E , Interleukin-13 , Interleukin-4 , Interleukin-5 , Leptin , Obesity
2.
Clin Transl Allergy ; 12(6): e12153, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35734271

ABSTRACT

Background: Obesity has often been associated with severe allergic asthma (AA). Here, we analyzed the frequency of different circulating CD4+T-cell subsets from lean, overweight and obese AA patients. Methods: Mononuclear cells from peripheral blood were obtained from 60 AA patients and the frequency of different CD4+T-cell subsets and type 1 regulatory B cells (Br1) was determined by cytometry. The effect of obese-related leptin dose on cytokine production and Treg cell function in AA-derived CD4+ T cell cultures was evaluated by ELISA and 3H thymidine uptake, respectively. Leptin levels were quantified in the plasma by ELISA. According to the BMI, patients were stratified as lean, overweight and obese. Results: AA severity, mainly among obese patients, was associated with an expansion of hybrid Th2/Th17 and Th17-like cells rather than classic Th2-like cells. On the other hand, the frequencies of Th1-like, Br1 cells and regulatory CD4+ T-cell subsets were lower in patients with severe AA. While percentages of the hybrid Th2/Th17 phenotype and Th17-like cells positively correlated with leptin levels, the frequencies of regulatory CD4+ T-cell subsets and Br1 cells negatively correlated with this adipokine. Interestingly, the obesity-related leptin dose not only elevated Th2 and Th17 cytokine levels, but also directly reduced the Treg function in CD4+ T cell cultures from lean AA patients. Conclusion: In summary, our results indicated that obesity might increase AA severity by favoring the expansion of Th17-like and Th2/Th17 cells and decreasing regulatory CD4+T cell subsets, being adverse effects probably mediated by leptin overproduction.

3.
Int Arch Allergy Immunol ; 183(6): 682-692, 2022.
Article in English | MEDLINE | ID: mdl-34959235

ABSTRACT

BACKGROUND: The regulatory CD8+ T (CD8+ Treg) cells play an important role in immune tolerance and have been implicated in several human autoimmune diseases. In this context, follicular helper T (TFH) cells contribute by controlling the antibody production. In mice, CD8+ Treg cells control the number and function of TFH cells however the role of human CD8+ Treg cells on the differentiation of naive CD4+ T cells into TFH cells has not been studied. OBJECTIVES: Here, we evaluated the ability of human CD183+ CD8+ Treg cells to suppress TFH cell differentiation in vitro. METHODS: Activated CD183+CCR7+CD45RA-CD8+ Treg and CD183+CD25highICOS+CD8+ Treg cells were sorted and cocultured with naïve CD4+ T cells under TFH differentiation condition. The differentiation of TFH cells was evaluated by flow cytometry. RESULTS: Our results showed that activated CD183+CD8+ Treg cells upregulated the expression of Forkhead box P3 transcription factor, inducible T-cell co-stimulator (ICOS), and CD25 compared to CD183-CD8+ T cells. The CD183+CD25highICOS+CD8+ Treg cells suppressed TFH cell differentiation and CD4+ T cell proliferation in vitro which was not observed when CD183+CCR7+CD45RA-CD8+ Treg were cocultured with naïve CD4+ T cells under TFH cell differentiation condition. CONCLUSION: These results suggest that CD25highICOS+CD183+CD8+ Treg cells may regulate autoimmune and inflammatory responses mediated by TFH cells.


Subject(s)
T Follicular Helper Cells , T-Lymphocytes, Regulatory , Animals , CD4-Positive T-Lymphocytes , CD8-Positive T-Lymphocytes , Cell Differentiation , Forkhead Transcription Factors , Mice , Receptors, CCR7 , T-Lymphocytes, Helper-Inducer
4.
Int Arch Allergy Immunol ; 182(12): 1155-1168, 2021.
Article in English | MEDLINE | ID: mdl-34348317

ABSTRACT

INTRODUCTION: Major depressive disorder (MDD) can impact the severity of allergic rhinitis (AR) and asthma (AA). Here, we evaluated the cytokine production by T-cells from AR and AA patients with or without MDD. The effect of serotonin on the in vitro T-cell response was also evaluated. METHODS: The cytokines produced by activated T-cells were measured by Luminex and flow cytometry. In some cell cultures, serotonin was added. RESULTS: MDD not only enhanced the production of Th2- and Th17-related cytokines, but also, the levels of interleukin (IL)-5 and IL-17 were directly correlated with the severity of depression and anxiety symptoms. As compared with AR, the levels of IL-17 were higher and the release of IL-10 was lower in activated T-cell cultures from AA patients, mainly those with MDD. In AA/MDD patients, the severity of anxiety symptoms and lung disease was directly correlated with Th17-like and hybrid Th2/Th17 cells, but inversely correlated with IL-10-secreting CD4+ T-cells. Finally, the addition of serotonin reduced the production of Th2- and Th17-related cytokines, but elevated IL-10 secretion in cell cultures from both AR and AA patients. CONCLUSIONS: Our findings suggest that not only the occurrence of MDD but also the severity of anxiety symptoms, may adversely affect the outcome of allergic reactions by favoring the production of cytokines implicated in the pathogenesis of AR and AA, a phenomenon that was attenuated by serotonin.


Subject(s)
Asthma/psychology , Cytokines/metabolism , Depressive Disorder, Major/immunology , Rhinitis, Allergic/psychology , Th17 Cells/immunology , Th2 Cells/immunology , Adult , Anxiety/complications , Anxiety/immunology , Anxiety/psychology , Asthma/complications , Asthma/diagnosis , Asthma/immunology , Biomarkers/metabolism , Case-Control Studies , Depressive Disorder, Major/complications , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/psychology , Female , Flow Cytometry , Humans , Male , Middle Aged , Patient Acuity , Rhinitis, Allergic/complications , Rhinitis, Allergic/diagnosis , Rhinitis, Allergic/immunology , Serotonin/pharmacology , Serotonin Receptor Agonists/pharmacology , Th17 Cells/drug effects , Th2 Cells/drug effects
5.
Immunology ; 162(3): 290-305, 2021 03.
Article in English | MEDLINE | ID: mdl-33112414

ABSTRACT

Elevated frequency of Th17-like cells expressing Toll-like receptors (TLRs) has been recently associated with relapsing-remitting multiple sclerosis (MS) pathogenesis, a chronic inflammatory demyelinating autoimmune disease of the central nervous system. We aimed to investigate the impact of current major depressive disorder (MDD) on the behaviour of these cells following in vitro stimulation with TLR2, TLR4, TLR5 and TLR9 agonists. Here, the level of both cell proliferation and cytokine production related to Th17/Tc17 phenotypes in response to TLR2 (Pam3C) and TLR4 (LPS) ligands was significantly higher in CD4+ and CD8+ T-cell cultures from MS/MDD patients when compared to non-depressed patients. These cytokine levels were positively associated with neurological disabilities in patients. No difference for responsiveness to TLR5 (flagellin) and TLR9 (ODN) agonists was observed. LPS, but not Pam3C, induced significant IL-10 release, mainly in patients without MDD. Interestingly, more intense expression of TLR2 and TLR4 on these cells was observed in MDD patients. Finally, in vitro addition of serotonin and treatment of MDD patients with selective serotonin reuptake inhibitors (SSRIs) reduced the production of Th17/Tc17-related cytokines by CD4+ and CD8+ T cells in response to Pam3C and LPS. However, only SSRI therapy diminished the frequency and intensity of TLR2 and TLR4 expression on circulating CD4+ and CD8+ T cells. In summary, although preliminary, our findings suggest that adverse events that elevate circulating levels of TLR2 and TLR4 ligands can affect MS pathogenesis, particularly among depressed patients.


Subject(s)
Antidepressive Agents, Second-Generation/therapeutic use , CD8-Positive T-Lymphocytes/drug effects , Depressive Disorder, Major/drug therapy , Fluoxetine/therapeutic use , Lymphocyte Activation/drug effects , Multiple Sclerosis, Relapsing-Remitting/immunology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Th17 Cells/drug effects , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism , Adult , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Case-Control Studies , Cell Proliferation/drug effects , Cells, Cultured , Cytokines/metabolism , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/immunology , Depressive Disorder, Major/psychology , Female , Humans , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/diagnosis , Multiple Sclerosis, Relapsing-Remitting/metabolism , Phenotype , Th17 Cells/immunology , Th17 Cells/metabolism , Treatment Outcome , Young Adult
6.
Am J Reprod Immunol ; 83(2): e13204, 2020 02.
Article in English | MEDLINE | ID: mdl-31674097

ABSTRACT

PROBLEM: Pregnancy appears to favor maternal antibody production. In contrast, by damaging follicular helper T cells (TFH ), HIV-1 infection compromises protective humoural immune response. Therefore, we aimed to investigate the frequency of different TFH -like cells in HIV-infected pregnant women (PW) before and after antiretroviral (ARV) therapy. METHOD OF STUDY: Peripheral blood mononuclear cells, CD4+ T and B cells, were obtained from asymptomatic HIV-1-infected non-PW and PW just before and after ARV therapy. In some experiments, healthy HIV-1-negative PW were also tested. The frequency of different TFH -like cell subsets was determined by flow cytometry. The plasma titers of IgG anti-tetanus toxoid (TT), anti-HBsAg, and anti-gp41 were determined by ELISA. The in vitro production of total IgG, IL-21, and hormones (estrogen and progesterone) was quantified also by ELISA. RESULTS: Our results demonstrate that antiretroviral (ARV) therapy was more efficient in elevating the percentage of circulating IL-21-secreting TFH cells in HIV-1-infected pregnant women (PW) than in non-pregnant patients (nPW). Moreover, in co-culture systems, CD4+ T cells from ART-treated PW were more efficient in assisting B cells to produce IgG production. The in vivo anti-HBsAg IgG titers after ARV therapy were also significantly higher in PW, and their levels were directly associated with both IL-21+ TFH frequency and plasma concentration of estrogen. CONCLUSION: In summary, our results suggest that pregnancy favors the recovery of TFH -like cells after ARV therapy in HIV-1-infected women, which could help these mothers to protect their newborns from infectious diseases by transferring IgG across the placenta.


Subject(s)
Anti-HIV Agents/pharmacology , HIV Infections/immunology , HIV-1 , Interleukins/metabolism , Pregnancy Complications, Infectious/immunology , T Follicular Helper Cells/metabolism , Adult , Anti-HIV Agents/therapeutic use , Antibodies, Bacterial/blood , Antibody Formation/drug effects , B-Lymphocytes/drug effects , CD4 Lymphocyte Count , Cells, Cultured , Coculture Techniques , Estrogens/blood , Female , HIV Antibodies/blood , HIV Envelope Protein gp41/immunology , HIV Infections/blood , HIV Infections/drug therapy , HIV-1/immunology , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/immunology , Humans , Immunoglobulin G/blood , Pregnancy , Pregnancy Complications, Infectious/blood , Progesterone/blood , Tetanus Toxoid/immunology , Young Adult
7.
J Neuroimmunol ; 330: 12-18, 2019 05 15.
Article in English | MEDLINE | ID: mdl-30769212

ABSTRACT

Due to their function in assisting B cells, TFH cells may be involved in the production of pathogenic IgG in neuromyelitis optica spectrum disorder (NMOSD). In the present study, the proportion of IL-6+ and IL-17+ TFH cell subsets was higher in NMOSD patients than healthy individuals. The frequency of both TFH cell subsets were directly associated with disease activity. By contrast, NMOSD patients with a higher proportion of IL-10+ TFH cell subsets showed a lower neurological disabilities score. In summary, all findings suggest that expansion of peripheral IL-6+ and IL-17+ TFH cells may be involved in the severity of NMOSD.


Subject(s)
Interleukin-17/blood , Interleukin-6/blood , Neuromyelitis Optica/blood , Neuromyelitis Optica/diagnosis , Severity of Illness Index , T-Lymphocytes, Helper-Inducer/metabolism , Adult , Biomarkers/blood , Cohort Studies , Female , Humans , Male , Middle Aged , Young Adult
8.
Eur J Immunol ; 48(8): 1376-1388, 2018 08.
Article in English | MEDLINE | ID: mdl-29719048

ABSTRACT

Excessive levels of proinflammatory cytokines in the CNS are associated with reduced serotonin (5-HT) synthesis, a neurotransmitter with diverse immune effects. In this study, we evaluated the ability of exogenous 5-HT to modulate the T-cell behavior of patients with MS, a demyelinating autoimmune disease mediated by Th1 and Th17 cytokines. Here, 5-HT attenuated, in vitro, T-cell proliferation and Th1 and Th17 cytokines production in cell cultures from MS patients. Additionally, 5-HT reduced IFN-γ and IL-17 release by CD8+ T cells. By contrast, 5-HT increased IL-10 production by CD4+ T cells from MS patients. A more accurate analysis of these IL-10-secreting CD4+ T cells revealed that 5-HT favors the expansion of FoxP3+ CD39+ regulatory T cells (Tregs) and type 1 regulatory T cells. Notably, this neurotransmitter also elevated the frequency of Treg17 cells, a novel regulatory T-cell subset. The effect of 5-HT in upregulating CD39+ Treg and Treg17 cells was inversely correlated with the number of active brain lesions. Finally, in addition to directly reducing cytokine production by purified Th1 and Th17 cells, 5-HT enhanced in vitro Treg function. In summary, our data suggest that serotonin may play a protective role in the pathogenesis of MS.


Subject(s)
Interferon-gamma/metabolism , Interleukin-17/metabolism , Multiple Sclerosis/pathology , Serotonin/metabolism , T-Lymphocytes, Regulatory/immunology , Th1 Cells/immunology , Th17 Cells/immunology , Adult , Brain/pathology , CD8-Positive T-Lymphocytes/immunology , Cell Proliferation/physiology , Cells, Cultured , Female , Humans , Lymphocyte Activation/immunology , Male , Multiple Sclerosis/immunology
9.
Immunology ; 154(2): 239-252, 2018 06.
Article in English | MEDLINE | ID: mdl-29168181

ABSTRACT

Signalling through Toll-like receptors (TLRs) may play a role in the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). In the present study, the expression of TLR-2, -4 and -9 was significantly higher on CD4+ and CD8+ T-cells from MS patients compared to healthy individuals. Following in-vitro activation, the proportion of interleukin (IL)-17+ and IL-6+ CD4+ and CD8+ T-cells was higher in the patients. In addition, the proportion of IFN-γ-secreting TLR+ CD8+ T-cells was increased in MS patients. Among different IL-17+ T-cell phenotypes, the proportion of IL-17+ TLR+ CD4+ and CD8+ T-cells producing IFN-γ or IL-6 were positively associated with the number of active brain lesions and neurological disabilities. Interestingly, activation of purified CD4+ and CD8+ T-cells with ligands for TLR-2 (Pam3Csk4), TLR-4 [lipopolysaccharide (LPS)] and TLR-9 [oligodeoxynucleotide (ODN)] directly induced cytokine production in MS patients. Among the pathogen-associated molecular patterns (PAMPs), Pam3Csk4 was more potent than other TLR ligands in inducing the production of all proinflammatory cytokines. Furthermore, IL-6, IFN-γ, IL-17 and granulocyte-macrophage colony-stimulating factor (GM-CSF) levels produced by Pam3Csk4-activated CD4+ cells were directly associated with disease activity. A similar correlation was observed with regard to IL-17 levels released by Pam3Csk4-stimulated CD8+ T-cells and clinical parameters. In conclusion, our data suggest that the expansion of different T helper type 17 (Th17) phenotypes expressing TLR-2, -4 and -9 is associated with MS disease activity, and reveals a preferential ability of TLR-2 ligand in directly inducing the production of cytokines related to brains lesions and neurological disabilities.


Subject(s)
Interleukin-17/metabolism , Multiple Sclerosis/etiology , Multiple Sclerosis/metabolism , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Toll-Like Receptors/metabolism , Adult , Biomarkers , Cytokines/genetics , Cytokines/metabolism , Disease Susceptibility , Female , Fluorescent Antibody Technique , Humans , Male , Multiple Sclerosis/diagnosis , Severity of Illness Index , Signal Transduction , Toll-Like Receptors/genetics , Young Adult
10.
J Neuroimmunol ; 307: 82-90, 2017 06 15.
Article in English | MEDLINE | ID: mdl-28495144

ABSTRACT

Different microbial antigens, by signaling through toll-like receptors (TLR), may contribute to Th17-mediated autoimmune diseases, such as neuromyelitis optica spectrum disorder (NMOSD). The objective of this study was to determine the proportion of different Th17-like cell subsets that express TLR in NMOSD patients. For this study, the frequency of different Th17 cell subsets expressing TLR subsets in healthy individuals (n=20) and NMOSD patients (n=20) was evaluated by cytometry. The peripheral levels of soluble CD14 (sCD14) and cytokines were determined by ELISA. Our results demonstrated that the proportion of peripheral CD4+ T cells expressing TLR2, 4 and 9 was significantly higher in NMOSD samples than in healthy subjects. In NMOSD, these cells are CD28+PD-1-CD57- and produce elevated levels of IL-17. Among different TLRs+ Th17-like subsets, the proportion of those that co-express IL-17 and IL-6 was significantly higher in NMOSD patients, which was positively correlated with sCD14 levels and EDSS score. By contrast, the percentage of TLRs+Treg17 cells (IL-10+IL-17+) was negatively related to sCD14 and the severity of NMOSD. In conclusion, the expansion of peripheral IL-6-producing TLR+ Th17-like cells in NMOSD patients was associated with both bacterial translocation and disease severity.


Subject(s)
Disabled Persons , Interleukin-6/metabolism , Neuromyelitis Optica/complications , Neuromyelitis Optica/pathology , Th17 Cells/metabolism , Toll-Like Receptors/metabolism , Adult , Antibodies/blood , Aquaporin 4/immunology , Cytokines/metabolism , Disability Evaluation , Female , Flow Cytometry , Humans , Male , Middle Aged , Neuromyelitis Optica/immunology , Statistics, Nonparametric , Young Adult
11.
J Reprod Immunol ; 121: 1-10, 2017 06.
Article in English | MEDLINE | ID: mdl-28482188

ABSTRACT

Pregnancy favors antibody production, and some evidence has suggested a direct effect of estrogen on B cells. The impact of pregnancy on circulating follicular helper T (TFH) cells, typically identified by the expression of CD45RO and CXCR5, has not been previously investigated. Here, the percentage of TFH cells, co-expressing or not PD-1, ICOS, or CXCR3 markers was significantly higher in pregnant women (PW) as compared with non-pregnant ones (nPW). Furthermore, the percentage of CXCR3+ TFH cells able to produce IL-6, IL-21, and IL-10 was significantly higher in PW than nPW. Interestingly, anti-CMV and anti-HBs antibody titers were significantly higher in the plasma of PW and were directly correlated with IL-21-producing CXCR3+ TFH cells. Finally, peripheral estrogen levels, but not progesterone, were positively related to either PD-1+ CXCR3+ TFH cells or plasma anti-CMV and anti-HBs IgG antibodies. In summary, our data suggests a positive effect of pregnancy on the proportion of CD4+ T cell subset specialized in helping B cells. This phenomenon, which could be related to the high estrogen levels produced during pregnancy, may help to explain why pregnancy favor humoral immunity.


Subject(s)
B-Lymphocytes/immunology , Cytomegalovirus/immunology , Germinal Center/immunology , Hepatitis B virus/immunology , T-Lymphocytes, Helper-Inducer/physiology , Adolescent , Adult , Antibodies, Viral/blood , Antibody Formation , Blood Circulation , Cells, Cultured , Estrogens/metabolism , Female , Humans , Inducible T-Cell Co-Stimulator Protein/metabolism , Interleukins/metabolism , Pregnancy , Programmed Cell Death 1 Receptor/metabolism , Receptors, CXCR3/metabolism , Young Adult
12.
J Neuroimmunol ; 299: 8-18, 2016 10 15.
Article in English | MEDLINE | ID: mdl-27725127

ABSTRACT

Vitamin D deficiency is an environmental risk factor for MS, a Th17 cell-mediated autoimmune disease that results in demyelination in the CNS. Therefore, we aimed to evaluate the ability of in vitro 1,25(OH)2D in modulating different Th17 cell subsets in MS patients in remission phase. In the present study, the production of Th17-related cytokines (IL-1ß, IL-6, IL-17, IL-22), as well as GM-CSF, was significantly higher in cell cultures from MS patients than in healthy subjects (HS). The 1,25(OH)2D reduced all pro-inflammatory cytokines essayed, mainly those released from HS cell cultures. The proportion of both IL-17+IFN-γ+ (CD4+ and CD8+) T cells and IL-17+IFN-γ-CD8+ T cells was positively related with neurological disorders, determined by EDSS score. The addition of 1,25(OH)2D reduced not only these pathogenic T cell subsets but elevated the percentage of IL-10-secreting conventional (FoxP3+CD25+CD127-CD4+) and non-conventional (IL-17+) regulatory-like T cells. Taken together, the results indicate that the active form of vitamin D should benefit MS patients by attenuating the percentage of pathogenic T cells. This effect could be direct and/or indirect, by enhancing classical and non-classical regulatory T cells.


Subject(s)
Interleukin-17/metabolism , Multiple Sclerosis/blood , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/metabolism , Vitamin D/pharmacology , Adolescent , Adult , Cells, Cultured , Female , Humans , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Male , Multiple Sclerosis/drug therapy , Vitamin D/therapeutic use , Young Adult
13.
Immunology ; 147(2): 212-20, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26781085

ABSTRACT

Multiple sclerosis (MS) is thought to be an autoimmune disorder. It is believed that immunological events in the early stages have great impact on the disease course. Therefore, we aimed to evaluate the cytokine profile of myelin basic protein (MBP)-specific T cells from MS patients in the early phase of the disease and correlate it to clinical parameters, as well as to the effect of in vitro corticoid treatment. Peripheral T cells from MS patients were stimulated with MBP with our without hydrocortisone for 5 days. The cytokines level were determined by ELISA. The number of active brain lesions was determined by MRI scans, and the neurological disabilities were assessed by Expanded Disability Status Scale scores. Our results demonstrated that MS-derived T cells responded to MBP by producing high levels of T helper type 1 (Th1) and Th17 cytokines. Although the production of interleukin-6 (IL-6), granulocyte-macrophage colony-stimulating factor, IL-17 and IL-22 was less sensitive to hydrocortisone inhibition, only IL-17 and IL-22 levels correlated with active brain lesions. The ability of hydrocortisone to inhibit IL-17 and IL-22 production by MBP-specific CD4(+) T cells was inversely related to the number of active brain lesions. Finally, the production of both cytokines was significantly higher in cell cultures from Afrodescendant patients and it was less sensitive to hydrocortisone inhibition. In summary, our data suggest that IL-17- and IL-22-secreting CD4(+) T cells resistant to corticoids are associated with radiological activity of the MS in early stages of the disease, mainly among Afrodescendant patients who, normally, have worse prognosis.


Subject(s)
Adrenal Cortex Hormones/pharmacology , Brain/drug effects , CD4-Positive T-Lymphocytes/drug effects , Drug Resistance , Hydrocortisone/pharmacology , Interleukin-17/immunology , Interleukins/immunology , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Myelin Basic Protein/immunology , Adolescent , Adult , Black or African American , Brain/immunology , Brain/metabolism , Brain/pathology , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Cells, Cultured , Disability Evaluation , Enzyme-Linked Immunosorbent Assay , Female , Humans , Interleukin-17/metabolism , Interleukins/metabolism , Magnetic Resonance Imaging , Male , Multiple Sclerosis, Relapsing-Remitting/diagnosis , Multiple Sclerosis, Relapsing-Remitting/ethnology , Multiple Sclerosis, Relapsing-Remitting/immunology , Multiple Sclerosis, Relapsing-Remitting/metabolism , Myelin Basic Protein/metabolism , Time Factors , Young Adult , Interleukin-22
14.
Hum Immunol ; 76(10): 701-10, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26429325

ABSTRACT

Aging is now a well-recognized characteristic of the HIV-infected population and both AIDS and aging are characterized by a deficiency of the T-cell compartment. The objective of the present study was to evaluate the impact of antiretroviral (ARV) therapy in recovering functional response of T cells to both HIV-1-specific ENV peptides (ENV) and tetanus toxoid (TT), in young and aged AIDS patients who responded to ARV therapy by controlling virus replication and elevating CD4(+) T cell counts. Here, we observed that proliferative response of T-cells to either HIV-1-specific Env peptides or tetanus toxoid (TT) was significantly lower in older antiretroviral (ARV)-treated patients. With regard to cytokine profile, lower levels of IFN-γ, IL-17 and IL-21, associated with elevated IL-10 release, were produced by Env- or TT-stimulated T-cells from older patients. The IL-10 neutralization by anti-IL-10 mAb did not elevate IFN-γ and IL-21 release in older patients. Finally, even after a booster dose of TT, reduced anti-TT IgG titers were quantified in older AIDS patients and it was related to both lower IL-21 and IFN-γ production and reduced frequency of central memory T-cells. Our results reveal that ARV therapy, despite the adequate recovery of CD4(+) T cell counts and suppression of viremia, was less efficient in recovering adequate immune response in older AIDS patients.


Subject(s)
Aging/immunology , Anti-HIV Agents/therapeutic use , CD4-Positive T-Lymphocytes/immunology , HIV Infections/drug therapy , HIV Infections/immunology , HIV-1/immunology , Adult , Age Factors , Aging/pathology , Antibodies, Viral/biosynthesis , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/virology , Case-Control Studies , Female , HIV Infections/pathology , HIV Infections/virology , Humans , Interleukin-10/biosynthesis , Interleukin-10/immunology , Interleukin-17/biosynthesis , Interleukin-17/immunology , Interleukins/biosynthesis , Interleukins/immunology , Male , Middle Aged , Peptides/pharmacology , Primary Cell Culture , Tetanus Toxoid/pharmacology , Viral Load/drug effects , Viral Proteins/pharmacology , Virus Replication/drug effects
15.
Brain Behav Immun ; 41: 182-90, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24882215

ABSTRACT

Dopamine (DA) is a neurotransmitter produced mainly in the central nervous system (CNS) that has immunomodulatory actions on T cells. As the multiple sclerosis (MS) has long been regarded as an autoimmune disease of CNS mediated by T cells, the objective of this study was to evaluate the impact of DA on in vitro functional status of T cells from relapsing-remitting (RR)-MS patients. Peripheral T-cells from RR-MS patients were activated by mitogens and cell proliferation and cytokine production were assayed by [(3)H]-thymidine uptake and ELISA, respectively. Our results demonstrated that DA enhanced in vitro T cell proliferation and Th17-related cytokines in MS-derived cell cultures. In addition, this catecholamine reduced Treg-related cytokines (IL-10 and TGF-ß) release by activated CD4(+) T cells. These DA-induced effects on T cells were mainly dependent on IL-6 production by both polyclonally-activated CD4(+) T cells and LPS-stimulated monocytes. Furthermore, the production of IL-17 and IL-6 by MS-derived T cells was directly related with neurological disability (EDSS score), and the release of these cytokines was less sensitive to glucocorticoid inhibition in MS patients than in control group, mainly after DA addition. In conclusion, our data suggest that DA amplifies glucocorticoid-resistant Th17 phenotype in MS patients, and this phenomenon could be, at least in part, due to its ability to induce IL-6 production by monocytes and CD4(+) T cells.


Subject(s)
Dopamine/pharmacology , Multiple Sclerosis, Relapsing-Remitting/immunology , Neuroimmunomodulation/physiology , Th17 Cells/immunology , Adult , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/metabolism , Cell Division , Cells, Cultured , Drug Resistance , Female , Humans , Interleukin-10/biosynthesis , Interleukin-10/genetics , Interleukin-6/biosynthesis , Interleukin-6/genetics , Lymphocyte Activation , Male , Middle Aged , Monocytes/drug effects , Monocytes/metabolism , Multiple Sclerosis, Relapsing-Remitting/metabolism , Phytohemagglutinins/pharmacology , Severity of Illness Index , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/genetics , Young Adult
16.
Immunology ; 143(4): 560-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24919524

ABSTRACT

Interleukin-6 (IL-6) has been implicated in the induction of pathogenic IL-17-producing T cells in autoimmune diseases, and studies evaluating the role of this cytokine in T-cell function in patients with multiple sclerosis (MS) are lacking. Our objective was to evaluate the role of IL-6 receptor (IL-6R) signalling on in vitro functional status of T cells from patients with relapsing-remitting MS during clinical remission. Our results demonstrated that, even during the remission phase, activated T cells from patients produce higher levels of IL-17, and this cytokine was positively correlated with disease severity, as determined by Expanded Disability Status Scale score. In the MS group, the blockade of IL-6R signalling by anti-IL-6R monoclonal antibody reduced IL-17 production and elevated IL-10 release by activated CD4(+) T cells, but it did not alter the production of these cytokines by activated CD8(+) T cells. Blockade of IL-6R signalling also reduced the ability of monocytes to up-regulate T helper type 17 phenotype in patients with MS. Finally, both cell proliferation and IL-17 release by CD4(+) and, mainly, CD8(+) T cells from patients with MS were less sensitive to hydrocortisone inhibition than control group. Interestingly, IL-6R signalling blockade restored the ability of hydrocortisone to inhibit both T-cell proliferation and IL-17 production. Collectively, these results suggest that IL-6 might be involved in MS pathogenesis by enhancing IL-17 production and reducing corticoid inhibitory effects on activated T cells.


Subject(s)
Interleukin-17/biosynthesis , Interleukin-6/metabolism , Multiple Sclerosis/immunology , Multiple Sclerosis/metabolism , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Adrenal Cortex Hormones/metabolism , Adrenal Cortex Hormones/pharmacology , Adult , Cytokines/biosynthesis , Drug Resistance , Female , Humans , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Male , Multiple Sclerosis, Relapsing-Remitting/immunology , Multiple Sclerosis, Relapsing-Remitting/metabolism , Receptors, Interleukin-6/metabolism , Signal Transduction , T-Lymphocyte Subsets/drug effects , Th17 Cells/immunology , Th17 Cells/metabolism , Young Adult
17.
Hum Immunol ; 74(9): 1080-7, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23777933

ABSTRACT

The pathogenesis of neuromyelitis optica (NMO) is influenced by a combination of genetic and environmental factors, including infectious agents. Several infectious diseases can both trigger or exacerbate autoimmunity. The objective of the present work was to evaluate the in vitro immune responsiveness to Escherichia coli (EC), Staphylococcus aureus (SA) and Candida albicans (CA) in remittent-recurrent NMO patients, and correlate it with the level of neurological disability. Our results revealed that the extent of lymphoproliferation and cytokine profile in response to SA- and CA-stimulated PBMC cultures was similar between NMO patients and healthy individuals. Nevertheless, a higher in vitro CD4(+) T cell proliferation associated with elevated IL-1ß, IL-6 and IL-17 release was observed in NMO-derived EC-stimulated cell cultures. Additionally, in these last cultures, the IL-10 production was significantly lower as compared with control group. The in vitro EC-induced levels of IL-6 and IL-17 were positively related with neurological disabilities. This higher tendency to produce Th17-related cytokines was proportional to the production of IL-23 and IL-6 by LPS-activated monocytes. Interestingly, elevated LPS levels were quantified in the plasma of NMO patients. The results suggest that a higher Th17-responsiveness to E. coli could be involved in the NMO pathogenesis.


Subject(s)
Candida albicans/immunology , Escherichia coli/immunology , Neuromyelitis Optica/immunology , Staphylococcus aureus/immunology , Th17 Cells/immunology , Adult , Antigens, Bacterial/immunology , Cell Proliferation , Cells, Cultured , Cytokines/metabolism , Female , Humans , Immunity, Cellular , Lipopolysaccharides/blood , Lipopolysaccharides/immunology , Lymphocyte Activation , Male , Middle Aged , Neuromyelitis Optica/microbiology , Neuromyelitis Optica/physiopathology , Young Adult
18.
Hum Immunol ; 74(9): 1051-6, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23792057

ABSTRACT

The number of HIV-infected young women has been increasing since the beginning of the AIDS epidemic. The objective of the present study was to investigate the impact of anti-retroviral treatment (ART) of HIV-1-infected pregnant women (PW) on cytokine profile of uninfected neonates. Our results demonstrated that higher levels of IL-1ß and TNF-α associated with lower IL-10 production were detected in the plasma obtained from neonates born from ART-treated PW. Furthermore, the production of TNF- α and IFN-γ was also significantly higher in polyclonally-activated T cells from those neonates. This elevated pro-inflammatory pattern detected by these activated-T cells was not associated to HIV-1 antigens sensitization. Finally, ART-exposed neonates showed to be born with lower weight, and it was inversely correlated with maternal peripheral TNF-a level. In summary, the data presented here suggest a significant disturbance in cytokine network of HIV-1-uninfected neonates exposed to potent anti-retroviral schemes during pregnancy.


Subject(s)
Cytokines/immunology , HIV Infections/drug therapy , HIV/immunology , Pregnancy Complications, Infectious/drug therapy , T-Lymphocytes/immunology , Adult , Antigens, Viral/immunology , Antiretroviral Therapy, Highly Active/adverse effects , Body Weight/drug effects , Cells, Cultured , Female , HIV Infections/immunology , Humans , Immunity, Maternally-Acquired/drug effects , Infant, Newborn , Lymphocyte Activation/drug effects , Pregnancy , Pregnancy Complications, Infectious/immunology , Young Adult
19.
Clin Immunol ; 148(2): 209-18, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23778260

ABSTRACT

Exogenous glucocorticoid plays an important role in controlling clinical relapses of multiple sclerosis (MS), but the response to this treatment differs among patients. In this study, T-cell proliferation and IL-17 production were less sensitive to hydrocortisone (HC) inhibition in MS patients than healthy individuals, mainly in CD8(+) compartment. Furthermore, in vitro IL-17 production was positively related with neurological disability and its release was proportional to IL-23 and IL-6 productions by LPS-activated monocytes. Interestingly, elevated LPS levels were quantified in the plasma of MS patients, and their levels were directly related to in vivo IL-6 production. Finally, HC-resistance in reducing IL-17 production by polyclonally-activated CD8(+) T cells was particularly observed among MS patients with higher in vivo LPS levels. In summary, the results indicate that T-cells derived from MS patients show an enhanced Th17-like phenotype that is directly associated with neurological disability, resistance to glucocorticoid inhibition and elevated bacterial translocation.


Subject(s)
Cytokines/metabolism , Glucocorticoids/pharmacology , Lipopolysaccharides/blood , Multiple Sclerosis/immunology , Th17 Cells/physiology , Adult , Cell Proliferation/drug effects , Cells, Cultured , Cytokines/antagonists & inhibitors , Cytokines/genetics , Female , Gene Expression Regulation/drug effects , Humans , Hydrocortisone/pharmacology , Lipopolysaccharides/metabolism , Male , Middle Aged , Monocytes/drug effects , Monocytes/immunology , Multiple Sclerosis/metabolism , Th17 Cells/drug effects , Young Adult
20.
J Clin Immunol ; 33(1): 179-89, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22948743

ABSTRACT

Neuromyelitis optica (NMO), also known as Devic's disease, is an autoimmune, inflammatory disorder of the central nervous system (CNS) in which the immune system attacks myelin of the neurons located at the optic nerves and spinal cord, thus producing a simultaneous or sequential optic neuritis and myelitis. The objective of this study was evaluated the background T-cell function of patients suffering from neuromyelitis optica (NMO), an autoimmune disorder of the central nervous system. In our study, the in vitro T cell proliferation and the production of Th1 cytokines were significantly lower in cell cultures from NMO patients, as compared with healthy individuals. In contrast, a dominant Th17-like phenotype, associate with higher IL-23 and IL-6 production by LPS-activated monocytes, was observed among NMO patients. The release of IL-21 and IL-6 by polyclonally activated CD4+ T cells was directly correlated to neurological disability. In addition, the in vitro release of IL-21, IL-6 and IL-17 was significantly more resistant to glucocorticoid inhibition in NMO patients. In conclusion, the results indicate dominant Th17-related response in NMO patients that was directly proportional to neurological disability. Furthermore, our results can help to explain why NMO patients trend to be more refractory to corticoid treatment.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Interleukin-6/biosynthesis , Interleukins/biosynthesis , Lymphocyte Activation/immunology , Neuromyelitis Optica/immunology , Adult , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/pathology , Cells, Cultured , Female , Humans , Interleukin-6/metabolism , Interleukins/metabolism , Male , Middle Aged , Neuromyelitis Optica/metabolism , Neuromyelitis Optica/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...